|Volume 7 Issue 92 Published - 14:00 UTC 08:00 EST 2-April-2005 Next Update - 14:00 UTC 08:00 EST 3-April-2005||Editor: Susan K. Boyer, RN
© Vidyya., Inc.
All rights reserved.
Non surgical cryoablation, "male lumpectomy" preserves function
(2 April 2005: VIDYYA MEDICAL NEWS SERVICE) -- A new nonsurgical treatment for prostate cancer preserves urinary and sexual function in a majority of men and offers an effective treatment, according to a study presented today at the Society of Interventional Radiology’s 30th Annual Scientific Meeting. The “male lumpectomy” uses focal cryoablation — freezing the tissue with extremely cold gas — to target only the tumor itself, which spares the healthy tissue in the prostate gland and associated anatomy, rather than destroying all of it as all traditional approaches do.
Prostate tumors do not tend to spread quickly, and up to 35 percent are solitary and unilateral. Thus, many of them can be treated with a local treatment, that pinpoints only the tumor, which is less likely to cause side effects. Sexual dysfunction and urinary incontinence are common complications of surgery, occurring in 75 percent and 10 percent of cases respectively, according to the published literature. Patients undergoing brachytherapy, another common treatment using implanted radioactive seed particles, have a 50 percent impotence rate in the long term. Both brachytherapy and surgery treat the whole prostate gland.
“Treating only the tumor instead of the whole prostate gland is a major and profound departure from the current thinking about prostate cancer,” said study author Gary Onik, MD, interventional radiologist, at Florida Hospital/Celebration Health, Celebration, Florida, who pioneered prostate cancer cryoablation in the early 1990s. “Focal cryoablation changes the whole picture in terms of complications, and the cancer control is as good as for any other treatment,” said Onik.
Cryoablation of the whole prostate gland has been approved by Medicare for over five years as a primary treatment for prostate cancer. Recent data show that cryoablation has a 10-year disease-specific survival rate of over 98%. Cryoablation is also the only procedure specifically approved by Medicare to treat patients with prostate cancer who have failed radiation therapy.
Prostate cancer is the most common cancer affecting American men. More than 230,000 men are diagnosed every year in the United States and 30,000 die from the disease. According the Prostate Cancer Foundation, a non-smoking American male is more likely to get prostate cancer than the next seven most common cancers combined. Historically, prostate cancer has been considered an older man’s disease, however the incidence is increasing in men in their 40s and 50s.
Focal Cryoablation for Prostate Cancer (Abstract 506)
Onik refers to focal cryoablation treatment for prostate cancer as “male lumpectomy,” reflecting the origins of the approach in the breast-sparing surgery that has in recent years replaced radical mastectomy as the preferred treatment for breast cancer. Nonsurgical cryoablation spares as much as possible of the prostate gland and its neurovascular bundles, limiting the side effects of incontinence and impotence that result from more radical prostate cancer treatments, such as surgical prostatectomy. It also represents an advantage over “watchful waiting,” because the surgical option is preserved, but the risk of missing the treatment window early in the cancer’s progression is lower.
3D GLOBAL BIOPSY MAPPING (Abstract 525)
Management of prostate cancer is in great part determined by the Gleason score, a cancer ranking method indicating tumor grade and stage, and the extent and location of the patient’s disease. A high Gleason score or bilateral cancer may preclude brachytherapy. Location of cancer in areas close to the neurovascular bundle makes nerve-sparing radical prostatectomy not feasible.
“This biopsy technique allows us to map the location of the tumor with tremendous precision and has the potential to greatly affect the decisions we make about treating prostate cancer,” Onik said.
In the study, 59 patients underwent transperineal mapping biopsies using ultrasound guidance. Cores were removed from their prostates at 5 mm intervals. Seventeen patients had bilateral biopsies and 42 had unilateral biopsies. Of the 42 patients who had had previously negative TRUS biopsies on one side (unilateral), 56 percent (23) were found to have cancer in the previously negative lobe. Of the 17 patients with bilateral biopsies, 15 had their treatment changed based on the new information from the biopsy. The new information provided by the biopsies had a major impact on cancer management for two-thirds of the patients.More information can be found at http://www.SIRweb.org.
Abstracts can be found at http://www.sirmeeting.org in the program section under scientific sessions.